Express News | Gongtong Pharmaceutical: Shareholder Li Minglei plans to reduce holdings by no more than 3% of shares.

BreakingsMay 20 18:10

Gongtong Pharmaceuticals reported revenue of 6.06 billion yuan in 2025, an increase of 12.97% year-over-year, while net losses widened by 165.88% year-over-year to 73.3591 million yuan.

Revenue increased by 12.97% to RMB 606 million, with cash flow turning positive from negative. However, net profit attributable to shareholders recorded a loss of RMB 73.3591 million, representing a year-on-year expansion of 165.88%. The main reasons include a decline in gross margin, significant increases in R&D and financial expenses, asset impairment, and concentrated losses at the end of the year. Despite accelerating capacity construction and overseas revenue increasing to 37.04% of total revenue, the new capacity has not effectively offset price and cost pressures, leading to continued pressure on profitability.

lanjinger.comApr 29 17:02

Common Pharmaceutical: 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Gongtong Pharmaceutical: Summary of the 2025 Annual Report

SZSIApr 29 00:00 · Announcements

Common Pharmaceutical: First Quarter Report for 2026

SZSIApr 29 00:00 · Announcements

Express News | The infant and child concept saw unusual movements in the closing session, with Hanshang Group's stock price surging to the daily limit in a straight line.

BreakingsJan 19 14:54